Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NMRA Stock Forecast 2026-2027
$2.32
Current Price
$422.33M
Market Cap
Buy 7
Hold 1
Sell 1
Wall St Analyst Ratings
Distance to NMRA Price Targets
+675.9%
To High Target of $18.00
+228.9%
To Median Target of $7.63
+29.3%
To Low Target of $3.00
NMRA Price Momentum
+12.6%
1 Week Change
-7.6%
1 Month Change
+231.4%
1 Year Change
+29.6%
Year-to-Date Change
-36.4%
From 52W High of $3.65
+279.7%
From 52W Low of $0.61
📊 TOP ANALYST CALLS
Did NMRA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Neumora is one of their latest high-conviction picks.
Latest NMRA Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, NMRA has a bullish consensus with a median price target of $7.63 (ranging from $3.00 to $18.00). The overall analyst rating is Strong Buy (8.4/10). Currently trading at $2.32, the median forecast implies a 228.9% upside. This outlook is supported by 7 Buy, 1 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Douglas Tsao at HC Wainwright & Co., projecting a 675.9% upside. Conversely, the most conservative target is provided by Paul Matteis at Stifel, suggesting a 29.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NMRA Analyst Ratings
7
Buy
1
Hold
1
Sell
NMRA Price Target Range
Low
$3.00
Average
$7.63
High
$18.00
Current: $2.32
Latest NMRA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NMRA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 31, 2026 | Guggenheim | Yatin Suneja | Buy | Reiterates | $14.00 |
| Mar 31, 2026 | Needham | Ami Fadia | Buy | Reiterates | $8.00 |
| Feb 17, 2026 | William Blair | Myles Minter | Outperform | Upgrade | $N/A |
| Jan 12, 2026 | Leerink Partners | Marc Goodman | Outperform | Initiates | $8.00 |
| Dec 1, 2025 | RBC Capital | Brian Abrahams | Outperform | Upgrade | $7.00 |
| Nov 17, 2025 | Stifel | Paul Matteis | Hold | Maintains | $3.00 |
| Oct 28, 2025 | Needham | Ami Fadia | Buy | Maintains | $8.00 |
| Oct 27, 2025 | Guggenheim | Yatin Suneja | Buy | Upgrade | $14.00 |
| Sep 16, 2025 | JP Morgan | Tessa Romero | Underweight | Downgrade | $N/A |
| Jul 16, 2025 | Mizuho | Graig Suvannavejh | Outperform | Maintains | $5.00 |
| May 13, 2025 | Needham | Ami Fadia | Buy | Reiterates | $5.00 |
| Apr 10, 2025 | Needham | Ami Fadia | Buy | Reiterates | $5.00 |
| Apr 2, 2025 | B of A Securities | Geoff Meacham | Underperform | Downgrade | $1.00 |
| Mar 10, 2025 | Guggenheim | Yatin Suneja | Neutral | Downgrade | $N/A |
| Mar 7, 2025 | Stifel | Paul Matteis | Hold | Downgrade | $2.00 |
| Mar 7, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Mar 4, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Reiterates | $4.00 |
| Mar 4, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $18.00 |
| Mar 4, 2025 | Needham | Ami Fadia | Buy | Reiterates | $5.00 |
| Feb 14, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $30.00 |
Neumora Therapeutics, Inc. (NMRA) Competitors
The following stocks are similar to Neumora based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Neumora Therapeutics, Inc. (NMRA) Financial Data
Neumora Therapeutics, Inc. has a market capitalization of $422.33M with a P/E ratio of -1.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -121.2%.
Valuation Metrics
Market Cap
$422.33M
Enterprise Value
$263.87M
P/E Ratio
-1.6x
PEG Ratio
0.3x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+43.2%
Current Ratio
5.9x
Debt/Equity
53.0x
ROE
-121.2%
ROA
-58.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Neumora Therapeutics, Inc. (NMRA) Business Model
About Neumora Therapeutics, Inc.
What They Do
Develops precision medicines for neurological disorders.
Business Model
The company utilizes computational data science to map disease biology and integrate it with clinical endpoints, focusing on precision psychiatry for conditions like depression and schizophrenia. By identifying patient subpopulations that may respond preferentially to treatments, Neumora Therapeutics aims to create tailored therapeutic interventions, thereby generating revenue through the development and potential sales of innovative treatments.
Additional Information
Neumora Therapeutics is positioned in the growing biotechnology sector, attracting investor interest due to its focus on advancements in mental health therapies and its potential to revolutionize the understanding and management of neurological diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
96
CEO
Mr. Henry O. Gosebruch
Country
United States
IPO Year
2023
Website
www.neumoratx.comNeumora Therapeutics, Inc. (NMRA) Latest News & Analysis
Latest News
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
15 days ago
Quick Summary
Neumora Therapeutics will participate in a fireside chat at the Needham Virtual Healthcare Conference on April 13, 2026, at 10:15 a.m. (Nasdaq: NMRA).
Why It Matters
Neumora's participation in a major healthcare conference highlights its visibility and potential to attract investor interest, especially regarding its innovative therapeutics pipeline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Neumora Therapeutics, Inc. (NMRA) held its Q4 2025 earnings call, discussing financial performance and strategic initiatives. Details on revenue and future outlook were provided.
Why It Matters
Neumora's Q4 2025 earnings reveal financial performance and strategic direction, impacting stock valuation and investor confidence in the company's future growth potential.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
NMRA-511 shows strong clinical effectiveness in a targeted population, comparable to pivotal studies of Rexulti and Auvelity.
Why It Matters
The positive data for NMRA-511 suggests strong competitive positioning against Rexulti and Auvelity, potentially boosting investor confidence and stock value in the pharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The Schall Law Firm is investigating Neumora Therapeutics (NASDAQ: NMRA) for potential securities law violations, including possible misleading statements to investors.
Why It Matters
Legal investigations can lead to stock volatility, potential financial penalties, or reputational damage for Neumora Therapeutics, impacting investor confidence and share prices.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Neumora Therapeutics downgraded from 'Strong Buy' to 'Hold' after KOASTAL-1's failure in MDD. Increased enrollment for KOASTAL-2 and KOASTAL-3, with topline data expected Q2 2026. NMRA-511 shows promise in Alzheimer's phase 1b.
Why It Matters
Neumora's downgrade signals reduced confidence in its MDD treatment amid uncertain trial outcomes, impacting stock sentiment. Positive Alzheimer's data offers potential but carries inherent risks.
Source: Seeking Alpha
Market Sentiment:
Negative
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
1 month ago
Quick Summary
Neumora Therapeutics, Inc. (Nasdaq: NMRA) will host a conference call on March 30, 2026, at 8:00 a.m. ET to discuss its Q4 and full year 2025 financial results and business updates.
Why It Matters
The upcoming conference call will reveal Neumora's financial performance and strategic direction, influencing stock valuation and investor sentiment. Key insights could impact investment decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About NMRA Stock
What is Neumora Therapeutics, Inc.'s (NMRA) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, Neumora Therapeutics, Inc. (NMRA) has a median price target of $7.63. The highest price target is $18.00 and the lowest is $3.00.
Is NMRA stock a good investment in 2026?
According to current analyst ratings, NMRA has 7 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $2.32. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NMRA stock?
Wall Street analysts predict NMRA stock could reach $7.63 in the next 12 months. This represents a 228.9% increase from the current price of $2.32. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Neumora Therapeutics, Inc.'s business model?
The company utilizes computational data science to map disease biology and integrate it with clinical endpoints, focusing on precision psychiatry for conditions like depression and schizophrenia. By identifying patient subpopulations that may respond preferentially to treatments, Neumora Therapeutics aims to create tailored therapeutic interventions, thereby generating revenue through the development and potential sales of innovative treatments.
What is the highest forecasted price for NMRA Neumora Therapeutics, Inc.?
The highest price target for NMRA is $18.00 from Douglas Tsao at HC Wainwright & Co., which represents a 675.9% increase from the current price of $2.32.
What is the lowest forecasted price for NMRA Neumora Therapeutics, Inc.?
The lowest price target for NMRA is $3.00 from Paul Matteis at Stifel, which represents a 29.3% increase from the current price of $2.32.
What is the overall NMRA consensus from analysts for Neumora Therapeutics, Inc.?
The overall analyst consensus for NMRA is bullish. Out of 11 Wall Street analysts, 7 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $7.63.
How accurate are NMRA stock price projections?
Stock price projections, including those for Neumora Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 3:26 AM UTC